Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity

Oct 25 2018

• By Emily Hayes

Related Content

Keytruda Is King, But Merck Faces Questions About Business Development

Oct 26 2018

Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory

Oct 18 2018

Pharma Q3 Results Preview: Merck Vs. Bristol In IO Showdown

Oct 22 2018

Key Cancer Data To Be Unveiled At ESMO In Munich

Oct 10 2018

Stealthy NGM And Bristol Emerge As Serious NASH Competitors

Apr 25 2017

Cardioxyl Buy To Resuscitate Bristol's CV Pipeline?

Nov 03 2015

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Apr 23 2018

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Apr 17 2018

Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

Sep 12 2018

Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO

Jun 06 2018

Bristol Touts Opdivo's Stability – And Diversity – In Strong Q2

Jul 27 2018

First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

Jul 30 2018

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Merck KGaA

Pfizer Inc.

Johnson & Johnson

Additional Topics

ImmunoOncology Sales & Earnings Companies Commercial Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.